OncoLink at ASCO 2000: Sunday, May 21
Due to severe weather causing flight delays, devoted OncoLink reporters Drs. Stripp and Levin drove from Philadelphia to New Orleans in order to provide coverage of ASCO 2000.
|Pictured from left to right Dr. Diana Stripp, Dr. William Levin, Dr. Joel Goldwein, Founder of OncoLink, and Maggie Hampshire, RN, BSN, OCN, Managing Editor|
3 Versus 6 Cycles of CMF in Breast Cancer Patients with 1 to 9 Positive Nodes: Results of the German Adjuvant Breast Cancer Group (GABG) III Trial Comparative Cost-Effectiveness of Paclitaxel-Cisplatin (TP) vs Cyclophosphamide-Cisplatin (CP) in Women with Advanced Epithelial Ovarian Cancer: Results from a Randomized Trial Does pretreatment PSA add to predicting long-term survival from prostate cancer? Induction Chemotherapy for High Grade Extremity Soft Tissue Sarcomas: Histologic Response and Correlation of Tumor Necrosis to Long Term Disease Free and Overall Patient Survival Multicenter Phase II/III Study of Oxaliplatin Plus Cyclophosphamide (C) [OXC] Versus Cisplatin (P) Plus Cyclophosphamide [CPC] in Advanced Chemonaive Ovarian Cancer (AOC) Patients (Pts): Final Results. Multicenter Phase II/III Study of Oxaliplatin Plus C The Role of Radiotherpay and Tamoxifen in the Management of Node Negative Invasive Breast Cancer </= 1.0 cm Treated with Lumpectomy: Preliminary Results of NSABP Protocol B-21